{'fraction_non_alphanumeric': 0.026863084922010397, 'fraction_numerical': 0.01559792027729636, 'mean_word_length': 5.243243243243243, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Letter: abnormal bone densitometry in patients with coeliac disease ‐ beyond malabsorption and sunlight exposure

week 0, 100 mg at week 2, and then 100 or 50 mg at week 6 according to body weight. Logistic regression analysis identified factors associated with clinical remission, including age at the time of enrolment, disease duration, Mayo score, Mayo subscore for endoscopy, and CRP and faecal calprotectin values. Clinical remission was obtained in eight (34.8%) patients. Clinical response to treatment was obtained in all patients. At univariate analysis, female sex and Mayo score ≤8 at entry were significantly related with clinical remission. After logistic regression only Mayo score ≤8 was significantly associated with clinical remission (Table 1). No side-effects were recorded during the induction course. These real-life results coming from primary gastroenterology centres confirm that the SC route is an effective route of administration for golimumab, obtaining good rates of remission, even after 8 weeks of treatment. It is noteworthy that the Mayo score was the single independent factor influencing the outcome in those patients.